Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 earnings is pegged at 14 cents per share, implying a year-over-year increase of 7.7%. Vertex’s earnings surpassed the Zacks ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Good morning and welcome to the Vertex Incorporated Fourth Quarter 2024 ... Beyond scaled customers, our new logo additions from our expanded ecosystem efforts are kicking into high gear.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex (NASDAQ:VERX – Free Report) had its price target reduced by Robert W. Baird from $62.00 to $45.00 in a research report report published on Friday morning,Benzinga reports. Robert W.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

In its fourth quarter 2024 investor letter, Parnassus Core Equity Fund emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Well thanks very much, everyone, for joining us for our next session with Vertex. My name is Dave Risinger ... ahead of payer coverage. That's why rev - why volumes will ramp ahead of revenues.